Long‐term regulation of local cytokine production following immunization in mice

Vaccines based on pathogen components require adjuvants to enhance the antigen‐specific adaptive immune response. Intramuscular injection of adjuvanted‐vaccines induces inflammatory cytokines and inflammatory nodules at the injection site within 48 hr after injection (Vaccine 2014; 32: 3393–401). In the present study, long‐term regulation of cytokine production was investigated at 3, 6, 24, and 48 hr, 5 and 7 days, and 2 and 4 weeks after immunization with human papilloma virus (HPV), diphtheria and tetanus toxoids combined with acellular pertussis (DTaP), Haemophilus influenza type B (Hib), and pneumococcal conjugated (PCV) vaccines in mouse models. The second dose was given 4 weeks later, and cytokine profiles were investigated 2, 5, and 7 days after re‐immunization. IL‐1β, IL‐6, granulocyte‐colony stimulating factor (G‐CSF), and MCP‐1 were produced from 3 hr and peaked at 48 hr after immunization with Cervarix in mice. IL‐4, MCP‐1, and TNF‐α peaked at 5 or 7 days after immunization with Gardasil. These cytokines decreased 7 days after immunization with Cervarix and Gardasil. After the second dose, similar responses were observed. Both vaccines induced neutrophil extracellular traps (NET) in inflammatory nodules. The peak amount of IL‐1β, IL‐6, G‐CSF, and MCP‐1 was observed on day 5 of immunization and that of IL‐4 on days 5‐7 of immunization with DTaP, but no increase in IL‐6 and G‐CSF was observed after re‐immunization. A similar response was noted after immunization with PCV13. An inflammatory response is essential for the development of adaptive immunity through the production of inflammatory cytokines.

[1]  T. Nakayama.  An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity. , 2016, Vaccine.

[2]  Zhi-heng Liu,et al.  Interleukin-6: an emerging regulator of pathological pain , 2016, Journal of Neuroinflammation.

[3]  F. Zepp.  Principles of Vaccination. , 2016, Methods in molecular biology.

[4]  P. Lopalco,et al.  Safety of human papillomavirus vaccines: a review , 2015, Expert opinion on drug safety.

[5]  S. Ikeda,et al.  Human Papillomavirus (HPV) Vaccination: Just the Facts. , 2015, Internal medicine.

[6]  S. Ikeda,et al.  Peripheral Sympathetic Nerve Dysfunction in Adolescent Japanese Girls Following Immunization with the Human Papillomavirus Vaccine. , 2015, Internal medicine.

[7]  S. Ikeda,et al.  Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. , 2014, Internal medicine.

[8]  Heidi J Larson,et al.  Tracking the global spread of vaccine sentiments: The global response to Japan's suspension of its HPV vaccine recommendation , 2014, Human vaccines & immunotherapeutics.

[9]  Y. Kashiwagi,et al.  Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines. , 2014, Vaccine.

[10]  Toshiyuki Shimizu,et al.  The attenuated inflammation of MPL is due to the lack of CD14-dependent tight dimerization of the TLR4/MD2 complex at the plasma membrane. , 2014, International immunology.

[11]  T. Seya,et al.  Beyond dsRNA: Toll-like receptor 3 signalling in RNA-induced immune responses. , 2014, The Biochemical journal.

[12]  Y. Kashiwagi,et al.  Production of inflammatory cytokines in response to diphtheria-pertussis-tetanus (DPT), haemophilus influenzae type b (Hib), and 7-valent pneumococcal (PCV7) vaccines , 2013, Human vaccines & immunotherapeutics.

[13]  C. Sommer,et al.  Differential gene expression of cytokines and neurotrophic factors in nerve and skin of patients with peripheral neuropathies , 2014, Journal of Neurology.

[14]  Helder I Nakaya,et al.  Immunity to viruses: learning from successful human vaccines , 2013, Immunological reviews.

[15]  C. Coban,et al.  Particulate Adjuvant and Innate Immunity: Past Achievements, Present Findings, and Future Prospects , 2013, International reviews of immunology.

[16]  Brittany D. Needham,et al.  Modulating the innate immune response by combinatorial engineering of endotoxin , 2013, Proceedings of the National Academy of Sciences.

[17]  C. Siegrist.  2 – Vaccine immunology , 2013 .

[18]  C. Sommer,et al.  Systematic review with meta-analysis: cytokines in fibromyalgia syndrome , 2011, BMC musculoskeletal disorders.

[19]  K. Ishii,et al.  Innate and adaptive immune responses to viral infection and vaccination. , 2011, Current opinion in virology.

[20]  S. Adachi,et al.  Singlet oxygen is essential for neutrophil extracellular trap formation. , 2011, Biochemical and biophysical research communications.

[21]  S. Levine,et al.  Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. , 2011, Cytokine & growth factor reviews.

[22]  B. Pulendran,et al.  Immunogenomics and systems biology of vaccines , 2011, Immunological reviews.

[23]  P. Marrack,et al.  Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo. , 2010, Blood.

[24]  Grace Y Chen,et al.  Sterile inflammation: sensing and reacting to damage , 2010, Nature Reviews Immunology.

[25]  Oberdan Leo,et al.  Key concepts in immunology. , 2010, Vaccine.

[26]  M. Yoneyama,et al.  Recognition of viral nucleic acids in innate immunity , 2010, Reviews in medical virology.

[27]  C. Cahill,et al.  TNF-α and neuropathic pain - a review , 2010, Journal of Neuroinflammation.

[28]  Arnaud M. Didierlaurent,et al.  AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1 , 2009, The Journal of Immunology.

[29]  A. Zychlinsky,et al.  NETs: a new strategy for using old weapons. , 2009, Trends in immunology.

[30]  E. De Gregorio,et al.  Mechanism of action of licensed vaccine adjuvants. , 2009, Vaccine.

[31]  O. Levy,et al.  Developmental Biology of the Innate Immune Response: Implications for Neonatal and Infant Vaccine Development , 2009, Pediatric Research.

[32]  T. Seya,et al.  Functional evolution of the TICAM‐1 pathway for extrinsic RNA sensing , 2009, Immunological reviews.

[33]  S. Tyring,et al.  Vaccine immunology , 2009, Dermatologic therapy.

[34]  T. Mitchell,et al.  Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant , 2008, Cellular and Molecular Life Sciences.

[35]  Andrew T. Kroger,et al.  Syncope after vaccination--United States, January 2005-July 2007. , 2008, MMWR. Morbidity and mortality weekly report.

[36]  C. Dinarello.  Historical insights into cytokines , 2007, European journal of immunology.

[37]  Thomas C. Mitchell,et al.  The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.

[38]  오윤석,et al.  Adjuvants , 2021, Visceral Leishmaniasis.

[39]  S. Normark,et al.  Neutrophil extracellular traps: casting the NET over pathogenesis. , 2007, Current opinion in microbiology.

[40]  D. Persing,et al.  Structure-Activity Relationship of Synthetic Toll-like Receptor 4 Agonists* , 2004, Journal of Biological Chemistry.

[41]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[42]  N. Qureshi,et al.  Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. , 1982, The Journal of biological chemistry.

[43]  S. Latt,et al.  Spectral studies on 33258 Hoechst and related bisbenzimidazole dyes useful for fluorescent detection of deoxyribonucleic acid synthesis. , 1976, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.